<![CDATA[LuTra Studio LLC]]>https://www.lutrastudio.studio/blogRSS for NodeWed, 30 Sep 2026 04:20:23 GMT<![CDATA[Biologics CMC 系列（七）：Biologics Analytical Method Validation——ICH Q2(R2) 與 Q14 實務指南]]>https://www.lutrastudio.studio/zh/post/biologics-analytical-method-validation-q2-q14-guide-zh6ab874449f7511779a1343e2Sun, 27 Sep 2026 16:14:17 GMTJason Lu<![CDATA[Biologics CMC Series VII: Biologics Analytical Method Validation—An ICH Q2(R2) and Q14 Guide]]>https://www.lutrastudio.studio/post/biologics-analytical-method-validation-q2-q14-guide6ab874449f7511779a1343e1Sun, 27 Sep 2026 16:14:11 GMTJason Lu<![CDATA[AI 藥物研發不只是找分子：Science 的「虛擬生技公司」如何重組新藥決策]]>https://www.lutrastudio.studio/zh/post/ai-drug-discovery-virtual-biotech-zh6ab7d1dbd852efceeddd7519Sat, 26 Sep 2026 18:59:18 GMTJason Lu<![CDATA[AI Drug Discovery Across the R&D Pipeline: What Virtual Biotech Can—and Cannot—Do]]>https://www.lutrastudio.studio/post/ai-drug-discovery-virtual-biotech6ab7d1dc27e1deabe9258e6fSat, 26 Sep 2026 18:59:16 GMTJason Lu<![CDATA[Rebuilding Human Germinal Center B Cells In Vitro: From Antibody Training Ground to a Manipulable Research Platform]]>https://www.lutrastudio.studio/post/human-germinal-center-b-cells-in-vitro6ab089a0ed85621288be876cMon, 21 Sep 2026 22:01:57 GMTJason Lu<![CDATA[在培養皿中重建人類生發中心 B 細胞：從抗體訓練場到可操作的免疫研究平台]]>https://www.lutrastudio.studio/zh/post/human-germinal-center-b-cells-in-vitro-zh6ab089a0ed85621288be876dMon, 21 Sep 2026 22:01:54 GMTJason Lu<![CDATA[Biologics CMC 系列（六）：Biologics Process Validation 製程確效—做完三批，就能放心量產嗎？]]>https://www.lutrastudio.studio/zh/post/biologics-process-validation-ppq-guide-zh6aa7cd4110c5b47f658438ddMon, 21 Sep 2026 04:55:38 GMTJason Lu<![CDATA[Biologics CMC Series, Part 6: Biologics Process Validation — Are Three Batches Enough for Commercial Manufacturing?]]>https://www.lutrastudio.studio/post/biologics-process-validation-ppq-guide6aa7cd4110c5b47f658438dcMon, 21 Sep 2026 04:55:36 GMTJason Lu<![CDATA[GLP-1 Longevity：Semaglutide 能模擬熱量限制並延緩老化嗎？]]>https://www.lutrastudio.studio/zh/post/glp-1-longevity-semaglutide-aging-zh6aa1251dff357ecb174ea5e4Sun, 13 Sep 2026 15:32:02 GMTJason Lu<![CDATA[GLP-1 Longevity: Can Semaglutide Mimic Calorie Restriction?]]>https://www.lutrastudio.studio/post/glp-1-longevity-semaglutide-calorie-restriction6aa0055e4086fafdb0d61b43Sun, 13 Sep 2026 15:31:18 GMTJason Lu<![CDATA[Biologics CMC 系列（五）：ICH Q12 Lifecycle Management——如何用 Established Conditions 與 PACMP 管理製程變更？]]>https://www.lutrastudio.studio/zh/post/ich-q12-lifecycle-management-biologics-cmc-zh6a9d850bc6495acaaf319490Sun, 06 Sep 2026 16:49:08 GMTJason Lu<![CDATA[Biologics CMC Series (5): ICH Q12 Lifecycle Management—Using Established Conditions and PACMPs to Manage Post-Approval Changes]]>https://www.lutrastudio.studio/post/ich-q12-lifecycle-management-biologics-cmc6a9d850c46a942797d04ba9bSun, 06 Sep 2026 16:49:06 GMTJason Lu<![CDATA[Ribosome Stem Cell Fate：CRISPR TAPIR 如何改變幹細胞命運？]]>https://www.lutrastudio.studio/zh/post/ribosome-stem-cell-fate-crispr-tapir-zh6a9ca99a471c913b0b05c939Sun, 06 Sep 2026 06:24:43 GMTJason Lu<![CDATA[Ribosome Stem Cell Fate: How CRISPR TAPIR Could Reshape Translation]]>https://www.lutrastudio.studio/post/ribosome-stem-cell-fate-crispr-tapir6a9ca99a471c913b0b05c93aSun, 06 Sep 2026 06:24:42 GMTJason Lu<![CDATA[Biologics CMC 系列（四）：Biologics Control Strategy—如何把製程、分析與法規要求整合成一套控制策略？]]>https://www.lutrastudio.studio/zh/post/biologics-control-strategy-cmc-guide-zh6a93e2bdba5fc19bcbb60970Sun, 30 Aug 2026 16:02:35 GMTJason Lu<![CDATA[Biologics CMC Series (4): Biologics Control Strategy—Integrating Process, Analytics, and Regulatory Requirements]]>https://www.lutrastudio.studio/post/biologics-control-strategy-cmc-guide6a93e2beba5fc19bcbb60973Sun, 30 Aug 2026 16:02:34 GMTJason Lu<![CDATA[mRNA LNP CMC 完整指南：從一篇 Review 延伸看原料、製程、分析與法規]]>https://www.lutrastudio.studio/zh/post/mrna-lnp-cmc-manufacturing-regulatory-guide-zh6a92c7f44f7694ed1ed9e009Sat, 29 Aug 2026 23:14:38 GMTJason Lu<![CDATA[mRNA-LNP CMC: A Practical Guide to Raw Materials, Manufacturing, Analytics, and Regulations]]>https://www.lutrastudio.studio/post/mrna-lnp-cmc-manufacturing-regulatory-guide6a930288f20ed98159c3a4c1Sat, 29 Aug 2026 23:14:37 GMTJason Lu<![CDATA[In Vivo CAR T 不再需要抗體標靶？Nature Materials 用「會啟動 T Cell 的 LNP」重新思考 mRNA Delivery]]>https://www.lutrastudio.studio/zh/post/in-vivo-car-t-ertlnp-mrna-delivery-zh6a8ac943c329a9b6d66722daSun, 23 Aug 2026 21:44:29 GMTJason Lu<![CDATA[Does In Vivo CAR T Still Need Antibody Targeting? How ERTLNP Rethinks mRNA Delivery]]>https://www.lutrastudio.studio/post/in-vivo-car-t-ertlnp-mrna-delivery6a8b468750b49c5960938ffdSun, 23 Aug 2026 21:44:26 GMTJason Lu